285 related articles for article (PubMed ID: 22037640)
1. Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active.
Brown SM; Holtzman M; Kim T; Kharasch ED
Anesthesiology; 2011 Dec; 115(6):1251-60. PubMed ID: 22037640
[TBL] [Abstract][Full Text] [Related]
2. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
3. HS-599: a novel long acting opioid analgesic does not induce place-preference in rats.
Lattanzi R; Negri L; Giannini E; Schmidhammer H; Schutz J; Improta G
Br J Pharmacol; 2001 Sep; 134(2):441-7. PubMed ID: 11564664
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception.
Brown SM; Campbell SD; Crafford A; Regina KJ; Holtzman MJ; Kharasch ED
J Pharmacol Exp Ther; 2012 Oct; 343(1):53-61. PubMed ID: 22739506
[TBL] [Abstract][Full Text] [Related]
5. Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction.
Robinson SE
CNS Drug Rev; 2002; 8(4):377-90. PubMed ID: 12481193
[TBL] [Abstract][Full Text] [Related]
6. Ring-constrained orvinols as analogs of buprenorphine: differences in opioid activity related to configuration of C(20) hydroxyl group.
Traynor JR; Guo L; Coop A; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1999 Dec; 291(3):1093-9. PubMed ID: 10565829
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological properties of TRK-820 on cloned mu-, delta- and kappa-opioid receptors and nociceptin receptor.
Seki T; Awamura S; Kimura C; Ide S; Sakano K; Minami M; Nagase H; Satoh M
Eur J Pharmacol; 1999 Jul; 376(1-2):159-67. PubMed ID: 10440101
[TBL] [Abstract][Full Text] [Related]
8. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors.
Lutfy K; Eitan S; Bryant CD; Yang YC; Saliminejad N; Walwyn W; Kieffer BL; Takeshima H; Carroll FI; Maidment NT; Evans CJ
J Neurosci; 2003 Nov; 23(32):10331-7. PubMed ID: 14614092
[TBL] [Abstract][Full Text] [Related]
9. Activities of mixed NOP and mu-opioid receptor ligands.
Spagnolo B; Calo G; Polgar WE; Jiang F; Olsen CM; Berzetei-Gurske I; Khroyan TV; Husbands SM; Lewis JW; Toll L; Zaveri NT
Br J Pharmacol; 2008 Feb; 153(3):609-19. PubMed ID: 18059322
[TBL] [Abstract][Full Text] [Related]
10. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist.
Huang P; Kehner GB; Cowan A; Liu-Chen LY
J Pharmacol Exp Ther; 2001 May; 297(2):688-95. PubMed ID: 11303059
[TBL] [Abstract][Full Text] [Related]
11. Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.
Cami-Kobeci G; Polgar WE; Khroyan TV; Toll L; Husbands SM
J Med Chem; 2011 Oct; 54(19):6531-7. PubMed ID: 21866885
[TBL] [Abstract][Full Text] [Related]
12. BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice.
Khroyan TV; Wu J; Polgar WE; Cami-Kobeci G; Fotaki N; Husbands SM; Toll L
Br J Pharmacol; 2015 Jan; 172(2):668-80. PubMed ID: 24903063
[TBL] [Abstract][Full Text] [Related]
13. Thienorphine induces antinociception without dependence through activation of κ- and δ-, and partial activation of μ- opioid receptor.
Zhou P; Li Y; Yong Z; Chen M; Zhang Y; Su R; Gong Z
Brain Res; 2020 Dec; 1748():147083. PubMed ID: 32871137
[TBL] [Abstract][Full Text] [Related]
14. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice.
Ide S; Minami M; Satoh M; Uhl GR; Sora I; Ikeda K
Neuropsychopharmacology; 2004 Sep; 29(9):1656-63. PubMed ID: 15100703
[TBL] [Abstract][Full Text] [Related]
15. The role of spinal opioid receptors in antinociceptive effects produced by intrathecal administration of hydromorphone and buprenorphine in the rat.
Tejwani GA; Rattan AK
Anesth Analg; 2002 Jun; 94(6):1542-6, table of contents. PubMed ID: 12032023
[TBL] [Abstract][Full Text] [Related]
16. Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors.
Zaveri NT; Journigan VB; Polgar WE
ACS Chem Neurosci; 2015 Apr; 6(4):646-57. PubMed ID: 25635572
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
[TBL] [Abstract][Full Text] [Related]
18. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.
Tao YM; Li QL; Zhang CF; Xu XJ; Chen J; Ju YW; Chi ZQ; Long YQ; Liu JG
Eur J Pharmacol; 2008 Apr; 584(2-3):306-11. PubMed ID: 18353307
[TBL] [Abstract][Full Text] [Related]
19. Gonadal hormone modulation of mu, kappa, and delta opioid antinociception in male and female rats.
Stoffel EC; Ulibarri CM; Folk JE; Rice KC; Craft RM
J Pain; 2005 Apr; 6(4):261-74. PubMed ID: 15820914
[TBL] [Abstract][Full Text] [Related]
20. Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells.
Hirota K; Okawa H; Appadu BL; Grandy DK; Devi LA; Lambert DG
Anesthesiology; 1999 Jan; 90(1):174-82. PubMed ID: 9915326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]